Sulfoxone

Summary

Sulfoxone (CHEMBL1570) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 404.5 Da · C14H16N2O6S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1570
Name	Sulfoxone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5351
Molecular formula	C14H16N2O6S3
Molecular weight	404.5
InChIKey	NEDPPCHNEOMTJV-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O

IUPAC name: [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid

Also known as: Aldesulfone, Aldesulphone, Sulfoxone

Parent form; salt/anhydrous children: CHEMBL1200580

Patent coverage: 533 distinct patent families (1,823 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,139 (62%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).